Results 11 to 20 of about 107 (101)
Факторы, ассоциированные с применением сниженных доз прямых оральных антикоагулянтов у больных с фибрилляцией предсердий [PDF]
, 2021 The objective was to study the factors associated with inappropriate reduced doses of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (AF) in real outpatient practice.Methods and materials.
В. А. Ионин +7 more
core +1 more source
Качественная клиническая практика, 2020 In last years, special attention has been paid in the Russian Federation (RF) to improving medical care for patients with atrial fibrillation (AF) and the prevention of thromboembolic complications (TEC).
A. A. Gruzdeva +2 more
doaj +1 more source
Качественная клиническая практика, 2023 Aim. To conduct a pharmacoeconomic analysis of the use of the drug Eliquis® (apixaban), belonging to direct oral anticoagulants (DOACs), for the treatment and prevention of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), including in patients ...
A. S. Kolbin +2 more
doaj +1 more source
Differences in the activity of coagulation cascade factors and concentrations of fibrinogen and d-dimer, in patients with pulmonary thromboembolism on direct oral anticoagulant therapy [PDF]
, 2023 Терапија директним оралним антикоагулансима (ДОАК) је према савременим водичима препоручена за лечење пацијената са плућном тромбоемболијом (ПТЕ). Није познато на који начин ДОАК-и утичу на активност фактора коагулације који нису њихова директна мета ...
Џудовић, Jелена
core +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran and rivaroxaban).Aim. To assess the influence of apixaban use on
A. V. Rudakova
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Background. For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (such as warfarin), antiplatelet therapy
A. V. Rudakova, V. A. Parfenov
doaj +1 more source
Prognosis and prevention of cardioembolic stroke in patients with atrial fibrillation
Медицинский совет, 2013 The article is a review of literature on the prognosis and prevention of stroke in patients with atrial fibrillation (AF). It is noted that the simple CHA2DS2-VASc calculator is a good predictor of the risk of stroke in AF.
V. А. Parfyonov, S. V. Verbitskaya
doaj +1 more source
NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE
Атеротромбоз, 2015 About 10% of the adult population is diagnosed with chronic kidney disease (CKD), and its presence is associated with a high risk of developing cardiovascular diseases including ventricular fibrillation (VF).
E. P. Panchenko
doaj +1 more source
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
Рациональная фармакотерапия в кардиологии, 2015 Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety.
D. A. Napalkov, A. A. Sokolova
doaj +1 more source
Качественная клиническая практика, 2023 Aim. To compare the effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (AF) for preventing stroke and systemic thromboembolism (embolism in the vessels of the systemic circulation, systemic embolism) in ...
A. S. Kolbin +2 more
doaj +1 more source